Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT071 in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT06333509Phase 2Not yet recruiting
- Sponsor
- CARsgen Therapeutics
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
01
Overview
Phase 2, open-label trial of CT071 in multiple myeloma (MM) and plasma cell leukaemia (PCL) (2 arms), sponsored by CARsgen Therapeutics. Primary endpoints: Evaluation of the Safety of CT071 and determination of Maximum Tolerated Dose (MTD) and Objective Response Rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
CT071
03
Conditions
multiple myeloma (MM)plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on NCT06333509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333509.